Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model - Takeaways - MDSpire

Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model

  • By

  • Sumit Bhattacharyya

  • Insug O-Sullivan

  • Joanne K. Tobacman

  • June 1, 2026

  • 0 min

Share

  • 1

    Arylsulfatase B (ARSB) treatment may enhance therapeutic responses when combined with Pembrolizumab in metastatic melanoma.

  • 2

    ARSB inhibits melanoma progression and improves survival by increasing apoptosis and altering cytokine expression.

  • 3

    The combination of ARSB and Pembrolizumab leads to decreased metalloproteinases and invasiveness in melanoma cells.

  • 4

    Decline in ARSB function promotes tumor progression through increased chondroitin 4-sulfation and disrupted signaling.

  • 5

    Recombinant human ARSB acts as a tumor suppressor in the B16F10 syngeneic melanoma model, reducing tumor size and metastases.

Original Source(s)

Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model

  • by Sumit Bhattacharyya, Insug O-Sullivan, Joanne K. Tobacman

  • June 1, 2026

Related Content

Repeated administration of autologous tumor-infiltrating lymphocytes (LM103 infusion) alongside immune checkpoint inhibitors results in sustained tumor regression in a patient with advanced mucosal melanoma: a case study and review of existing literature

Comparative efficacy of therapeutic modalities for metastatic uveal melanoma: a systemic review and network meta-analysis

Generation of functional canine TIL products for solid tumors